Foley & Larder LLP represented TCG Crossover, lead investor. Adverum Biotechnologies has agreed to sell approximately 106.25 million shares of its common stock at a price per share...
You must be a Standard 1 Year member to access this content.
Foley & Larder LLP represented investor TCG Crossover. Silence Therapeutics plc (Nasdaq: SLN), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing...
You must be a Standard 1 Year member to access this content.
Foley & Larder LLP represented TCG Crossover, as lead investor. Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension,...
You must be a Standard 1 Year member to access this content.
Foley & Lardner LLP represented TCGX as co-lead investor. Alkeus Pharmaceuticals closed its $150 million Series B financing for Alkeus Pharmaceuticals. TCGX was joined by Bain...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented TCG Crossover in the deal. TCG Crossover (“TCGX”) announced the closing of its second fund, TCGX Fund II, with...
You must be a Standard 1 Year member to access this content.
Foley & Lardner LLP represented TCGX as a lead investor in the financing of COMPASS Pathways. COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to...
You must be a Standard 1 Year member to access this content.
